Respiratory Investigation is a leading peer-reviewed journal published by Elsevier, dedicated to advancing the field of Pulmonary and Respiratory Medicine. Since its inception in 2012, the journal has grown to become a vital resource for researchers, clinicians, and students alike, providing a platform for high-quality research articles, reviews, and clinical studies. With a commendable impact factor and ranked in the Q2 category of Scopus' 2023 metrics, it stands at rank #57 out of 155 in its field, illustrating its importance and influence within the academic community. Although the journal operates on a subscription basis, it remains committed to disseminating essential findings that enhance the understanding and treatment of respiratory diseases. Set against the innovative backdrop of the Netherlands, Respiratory Investigation not only serves as a conduit for scholarly exchange but also plays a critical role in shaping future research directions and clinical practices.

AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY, published by the American Physiological Society, stands as a prominent peer-reviewed journal dedicated to advancing the field of lung cellular and molecular physiology. With an impressive impact factor, the journal serves as a crucial platform for disseminating high-quality research focused on the intricate mechanisms underlying pulmonary function and disease. Established in 1989, this journal has consistently ranked within the top quartiles across various categories, including Q1 in Physiology and Pulmonary and Respiratory Medicine, highlighting its significance in the scientific community. The journal covers a wide scope of topics pertinent to cell biology and physiology, catering to the needs of researchers, professionals, and students seeking to explore and contribute to this vital area of study. Although currently not offering open access, it provides comprehensive access options for subscribers, ensuring that vital research is communicated effectively to the global scientific community. With a commitment to fostering innovation and inspiring future studies, the AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY remains an essential resource for those engaged in lung research.

RESPIROLOGY is a prestigious academic journal that focuses on the field of Pulmonary and Respiratory Medicine, publishing high-quality research and comprehensive reviews that contribute significantly to the understanding and management of respiratory health. As a distinguished publication of WILEY, it has established a strong presence in the academic world with an impressive impact factor and ranked in the Q1 category, recognized for its influence and innovation in the field. RESPIROLOGY is committed to disseminating cutting-edge research from 1996 through 2024, appearing regularly in SCOPUS with a rank of #14 out of 155, placing it in the rarefied 91st percentile among its peers. The journal invites contributions from researchers, professionals, and students, fostering a collaborative space for advancing knowledge in pulmonary medicine. Although it does not offer open access, its readership spans globally, indicating the high regard in which it is held within the scientific community.

Therapeutic Advances in Respiratory Disease is a prestigious open-access journal published by SAGE Publications Ltd, based in the United Kingdom. Since its inception in 2007, it has established itself as a leading platform for the dissemination of cutting-edge research in the fields of pulmonary and respiratory medicine and pharmacology. With an impressive impact factor and ranking—showing it is in the Q1 quartile in both Pharmacology (medical) and Pulmonary and Respiratory Medicine as of 2023—the journal's commitment to high-quality research is evident. In 2023, it ranks #32 out of 155 in Pulmonary and Respiratory Medicine and #57 out of 272 in Medical Pharmacology, positioning it in the 79th percentile across these disciplines. Open access since 2018, the journal ensures that its valuable content is readily accessible to a global audience of researchers, healthcare professionals, and students, facilitating the rapid exchange of knowledge that is crucial in the ever-evolving landscape of respiratory health. The journal's objectives include advancing understanding of respiratory diseases through innovative research and promoting the development of therapeutic strategies that improve patient outcomes, making it an essential resource for those dedicated to respiratory medicine.

The Egyptian Journal of Chest Diseases and Tuberculosis is a premier Open Access journal published by Wolters Kluwer Medknow Publications, focusing on the latest advancements in the fields of respiratory diseases, pulmonary medicine, and tuberculosis management. With an ISSN of 0422-7638 and an E-ISSN of 2090-9950, this journal aims to disseminate high-quality research, reviews, and clinical insights that advance the understanding and treatment of chest diseases. Since its transition to Open Access in 2018, the journal has garnered increased visibility, enabling researchers across the globe to contribute and access valuable content without barriers. Situated in India, the journal is dedicated to bridging the gap between clinical practice and research, emphasizing the significance of innovative therapeutic strategies and public health approaches in combating respiratory illnesses. We invite researchers, healthcare professionals, and students to engage with our publications as we continue to foster knowledge and foster collaboration within the global medical community.

BMC Pulmonary Medicine is a leading open access journal dedicated to the field of pulmonary and respiratory medicine, published by BMC since its inception in 2001. With an ISSN of 1471-2466, this journal plays a pivotal role in advancing knowledge and research dissemination in its field, maintaining a prominent position with a 2023 Scopus ranking of #65 out of 155 journals, placing it within the 58th percentile of the category. Based in the United Kingdom, it operates under a collaborative mission to provide unrestricted access to vital research, contributing to the global understanding of respiratory health issues. The journal is recognized for its commitment to high-quality, peer-reviewed research, as evidenced by its Q2 category designation in Pulmonary and Respiratory Medicine. BMC Pulmonary Medicine aims to foster innovation and scholarship among researchers, professionals, and students, making it an indispensable resource for anyone engaged in pulmonary research and practice. The journal, accessible to everyone, enables the dissemination of impactful research that can influence clinical practice and policy worldwide.

HEART & LUNG is a premier academic journal published by MOSBY-ELSEVIER, focusing on the critical intersections of cardiology, critical care, and respiratory medicine. Since its inception in 1973, the journal has established a significant reputation within the medical community, as evidenced by its impressive Q2 ranking in key categories such as Cardiology and Cardiovascular Medicine, Critical Care and Intensive Care Medicine, and Pulmonary and Respiratory Medicine for the year 2023. With a dedicated readership comprising researchers, healthcare professionals, and students, HEART & LUNG serves as a vital platform for disseminating cutting-edge research, clinical innovations, and comprehensive reviews that influence practice standards and enhance patient care. While it currently does not offer Open Access options, readers can access a wealth of information pivotal to the advancement of medical knowledge and practice through conventional subscription. Explore the latest findings and contribute to the ever-evolving landscape of cardiovascular and respiratory health through this esteemed journal.

THORAX is a premier academic journal dedicated to advancing knowledge in the field of Pulmonary and Respiratory Medicine. Published by the esteemed BMJ Publishing Group in the United Kingdom, this journal has been a pivotal resource for researchers and clinicians since its inception in 1946. With a remarkable ranking of #6 out of 155 in its category, THORAX holds a prestigious position within the top 4% of its field, as indicated by its 2023 Q1 quartile classification and a strong Scopus ranking. The journal focuses on publishing high-quality research, reviews, and clinical studies that are essential for understanding respiratory diseases and their management. Although it is not an open-access journal, THORAX provides vital contributions to the academic community, fostering dialogue and innovation in pulmonary medicine. As it approaches its converged years, concluding in 2024, researchers, professionals, and students are encouraged to explore its rich repository of knowledge, while engaging with the most current advancements in the field.

RESPIRATORY RESEARCH is a leading open-access journal published by BMC, dedicated to advancing the field of pulmonary and respiratory medicine. Since its inception in 2000, this journal has provided a vital platform for disseminating high-quality research, covering a broad spectrum of topics from basic science to innovative clinical practices in respiratory health. With an impressive impact factor and a Q1 ranking in the Pulmonary and Respiratory Medicine category, RESPIRATORY RESEARCH is recognized for its significant contribution to the literature, currently positioned at rank #19 out of 155 in the Scopus database, highlighting its relevance and influence within the medical community. The journal’s commitment to open access ensures that all articles are freely available to researchers, professionals, and students, fostering collaboration and knowledge sharing in the field. With its convergence years spanning from 2000 to 2024, RESPIRATORY RESEARCH remains at the forefront of respiratory medicine research, making it an essential resource for all stakeholders in this vital medical domain.

Respiratory Care is a leading journal in the fields of Critical Care, Intensive Care Medicine, and Pulmonary and Respiratory Medicine, published by DAEDALUS ENTERPRISES INC. With a history dating back to 1973 and continuing through 2024, this journal serves as a vital platform for disseminating innovative research findings, clinical practices, and advancements in respiratory healthcare. The journal is recognized for its impact, reflected in its impressive Q2 quartile rankings across several categories in 2023, demonstrating its relevance and influence in the medical community. Although it is not an Open Access publication, it provides critical insights and foster discussions aimed at enhancing patient care and treatment protocols for respiratory diseases. The journal is indexed in notable databases, ensuring wide visibility and accessibility of its content to researchers, professionals, and students dedicated to advancing knowledge and practice in respiratory care.